scholarly journals Fenspiride use in acute respiratory infections in children

2019 ◽  
pp. 120-123
Author(s):  
N. G. Kolosova ◽  
M. D. Shakhnazarova
Keyword(s):  
Safety Profile ◽  
Respiratory Diseases ◽  
Respiratory Infections ◽  
Economic Problem ◽  
Acute Respiratory Infections ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Acute Respiratory Diseases ◽  
Anti Inflammatory

Acute respiratory infections are the most common pathology in childhood, representing not only a medical but also a socio-economic problem. Numerous studies on the use of anti-inflammatory therapy in ARI have shown high efficacy and safety profile of fenspiride. The combination of anti-inflammatory, antiallergic, and antispasmodic properties ensures the success of fenspiride in the treatment of acute respiratory diseases in children. Fenspiride reduces symptoms of ARI, accelerates recovery, reduces the need for additional prescription of other drugs.

Newer Virus Diseases: Clinical Differentiation of Acute Respiratory Infections

PEDIATRICS ◽  
1961 ◽  
Vol 27 (1) ◽  
pp. 44-44
Author(s):  
DAVID T. KARZON
Keyword(s):  
Respiratory Diseases ◽  
Small Volume ◽  
Respiratory Infections ◽  
Daily Practice ◽  
Clinical Aspects ◽  
Acute Respiratory Infections ◽  
Viral Etiology ◽  
Virus Diseases ◽  
Acute Respiratory Diseases ◽  
Basic Concepts

Acute respiratory diseases, especially those of viral etiology, occupy a goodly proportion of the attention of the pediatrician in his daily practice. In this small volume, Dr. Adams attempts to bring together the rapidly appearing information regarding recent discoveries and innovations in virology and correlate them with clinical aspects of respiratory infection. Sections are devoted to introducing basic concepts in virology and to anatomic and physiologic aspects of the respiratory system in relation to infection.

scholarly journals Acute respiratory diseases: progression features, pharmaceutical therapy

2018 ◽  
pp. 82-88
Author(s):  
N. V. Orlova ◽  
T. G. Suranova
Keyword(s):  
Respiratory Diseases ◽  
Respiratory Infections ◽  
Intracellular Bacteria ◽  
Acute Respiratory Infections ◽  
Pharmaceutical Therapy ◽  
Wide Range ◽  
Acute Respiratory Diseases ◽  
High Concentrations ◽  
Acute Respiratory Viral Infection ◽  
Social Importance

Acute respiratory diseases (ARD) are widespread diseases and are of great social importance. Diagnosis of acute respiratory infections implies the damage to the respiratory system caused by a wide range of pathogens. Among the pathogens of acute respiratory infections are viruses of acute respiratory viral infection (ARVI) group, including influenza, as well as fungal and bacterial pathogens, which include intracellular bacteria: mycoplasma and chlamydia. Diseases caused by intracellular pathogens are treated by antibacterial drugs that can easily penetrate the cells and create there high concentrations.

SOME ASPECTS OF THE MUKOAKTIV THERAPY OF ACUTE RESPIRATORY DISEASES IN THE CHILDREN

2013 ◽  
Vol 4 (3) ◽  
pp. 61-64
Author(s):  
Natalya Dmitriyevna Soroka
Keyword(s):  
Clinical Characteristics ◽  
Respiratory Diseases ◽  
Sick Child ◽  
Respiratory Infections ◽  
Early Age ◽  
Efficacy And Safety ◽  
Acute Respiratory Disease ◽  
Dry Extract ◽  
Post Marketing ◽  
Acute Respiratory Diseases

The article presents the data on acute respiratory infections in children, defined the characteristics of the modern trends, gives a brief clinical characteristics of protracted variants of acute respiratory disease. The reasonability of mykoaktive therapy in the treatment of acute respiratory diseases. Presents data post marketing study of efficacy and safety of mykoaktive preparation Prospan (Manufacturer Engelhard Arzneimittel, Germany). Prospan marked by a high secretolytic, bronchospasmolytic effects and safety of dry extract of leaves of ivy of the treatment of acute respiratory diseases, including children of early age, as well as the opportunity to personalize the application of various medicinal forms preparation and ways of delivery to the organism of a sick child.

scholarly journals FRI0458 EFFICACY AND SAFETY OF PCV13 VACCINATION IN JIA PATIENTS WITH SYSTEMIC MANIFESTATIONS ON TOCILIZUMAB AND CANAKINUMAB TREATMENT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 826.1-827
Author(s):  
D. Vankova ◽  
E. Alexeeva ◽  
T. Dvoryakovskaya ◽  
K. Isaeva ◽  
A. Chomakhidze ◽  
...  
Keyword(s):  
Respiratory Infections ◽  
Clinical Effectiveness ◽  
Immunosuppressive Drugs ◽  
Acute Stage ◽  
Acute Respiratory Infections ◽  
Efficacy And Safety ◽  
Vaccine Response ◽  
Protection Level ◽  
Acute Group ◽  
Increased Risk

Background:The need for continuous use of immunosuppressive drugs leads to increased risk of developing infectious diseases in children with juvenile idiopathic arthritis with systemic manifestation (sJIA). Questions about choosing the optimal vaccination time and the effect of different classes of therapy on vaccination effectiveness are still open.Objectives:To study clinical and laboratory effectiveness of PCV13-vaccination in children with sJIA on tocilizumab (TOC) and canakinumab (CAN) treatment depending on disease activity stage.Methods:Prospective cohort study included 2 groups of sJIA patients: in stable remission (Remission group, n=53) receiving CAN (n=10) or TOC (n=43) treatment, and in acute stage of disease (Acute group, n=25) which started to received CAN (n=7) or TOC (n=18) either before vaccination (Acute Treated Before subgroup, n=17) or after vaccination (Acute Treated After subgroup, n=8). 0.5 ml of the 13-valent PCV was administered once subcutaneously. Efficacy was evaluated by achieving of protection level of anti-pneumococcal antibodies after 4 weeks and by clinical indicators after 6 month follow-up: frequency of acute respiratory infections, frequency of antibiotics treatment courses, frequency of temporary withdrawal of biologics treatment due to severe infections. Frequency of events were counted per patients-years.Results:Four weeks after vaccination, protection level of anti-pneumococcal antibodies was achieved by for 36 (67.9%) patients in Remission group, 16 (64%) patients in Acute group (intergroup p=0.932), and in 8 (47.06%) patients in Acute Treated Before subgroup and in 8 (100%) patients in Acute Treated After subgroup (intersubgroup p=0.022). PCV13 have shown high clinical effectiveness in both Remission group and Acute group. Reducing of acute respiratory infections frequency was as follows: from 4.57 to 2.15 episodes per patient-year in Remission group (p<0.001) and from 4.32 to 1.28 per patient-year in Acute group (p<0.001).Duration of antibiotics treatment reduced from 2.31 to 0.81 weeks per 1 patient-year in Remission group (p<0.001) from 1.97 to 0.74 in Acute group (p<0.001). Among patients who were previously treated with biologics, frequency of therapy withdrawal reduced from 4.34 to 2.42 per patient-year in Remission group (p<0.001) and from 3.53 to 1.18 in Acute Treated Before subgroup (p=0.002). The incidence of reactions to vaccination of PCV13 (local hyperemia, pain, subfebrile temperature) was similar in groups (22 (41.5%) for Remission group and 7 (28%) for Acute group, p= 0.319).Conclusion:Vaccination with the 13-valent PCV has demonstrated high clinical efficacy and safety in children with sJIA both in the acute stage of the disease and during remission. Vaccination of patients in acute stage of sJIA before treatment has advantages over vaccination during remission or after prolonged immunosuppressive therapy in terms of achieving an adequate vaccine response.Disclosure of Interests:Dariya Vankova: None declared, Ekaterina Alexeeva Grant/research support from: Roche, Pfizer, Centocor, Novartis, Speakers bureau: Roche, Novartis, Pfizer., Tatyana Dvoryakovskaya: None declared, Ksenia Isaeva: None declared, Aleksandra Chomakhidze: None declared, Rina Denisova: None declared, Anna Mamutova: None declared, Anna Fetisova: None declared, Marina Gautier: None declared, Elizaveta Krekhova: None declared, Meyri Shingarova: None declared, Ivan Kriulin: None declared, Anastasiya Kontorovich: None declared, Olga Galkina: None declared, Tatyana Radygina: None declared, Irina Zubkova: None declared, Natalia Tkachenko: None declared, Yanina Orlova: None declared, Mariya Kurdup: None declared, Anna Ismailova: None declared, Alina Alshevskaya: None declared, Andrey Moskalev: None declared, Olga Lomakina: None declared

scholarly journals Monostrain and multistrain probiotics for respiratory diseases in children

2020 ◽  
Vol 4 (11) ◽  
pp. 698-704
Author(s):  
E.S. Dzottsoeva ◽  
◽  
A.V. Gorelov ◽  
◽  
Keyword(s):  
Respiratory Diseases ◽  
Respiratory Infections ◽  
Lactobacillus Rhamnosus ◽  
Human Organism ◽  
High Morbidity ◽  
Acute Respiratory Infections ◽  
Bifidobacterium Lactis ◽  
Impaired Performance ◽  
Vital Functions ◽  
Multistrain Probiotics

Acute respiratory infections (ARIs) in children are common conditions characterized by high morbidity. ARIs account for up to 75% of all cases of antibiotic use. Dysbiosis results in the impaired performance of vital functions, i.e., digestion, synthesis, colonization resistance, and the regulation of immune system. Probiotics are one of the effective tools to affect the composition of gut microbiota and to restore its metabolic activity. Probiotics, their effects on human organism, and their use in various diseases have received an enormous attention. Meanwhile, the use of antibiotics and the etiological diversity of ARIs account for the lack and irrationality of extensive preventive measures (as in flu) and raise the interest in non-specific prophylaxis. Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subsp. Lactis BB-12 are well-studied strains. Lactobacillus plantarum LP01 and LP02, Lactobacillus rhamnosus LR04 and LR05, and Bifidobacterium lactis BS01 used as monostrain probiotics are also of interest. Multistrain probiotics are gaining traction. However, these probiotics are understudied and require more attention. KEYWORDS: microbiome, monostrain probiotics, multistrain probiotics, acute respiratory infections, antibiotic-associated diarrhea, antibiotic-associated syndrome, Lactobacillus rhamnosus, Bifidobacterium lactis. FOR CITATION: Dzottsoeva E.S., Gorelov A.V. Monostrain and multistrain probiotics for respiratory diseases in children. Russian Medical Inquiry. 2020;4(11):698–704. DOI: 10.32364/2587-6821-2020-4-11-698-704.

scholarly journals Etiological characteristics of acute respiratory diseases in servicemen of the Western military district in 2014-2019

2020 ◽  
Vol 22 (1) ◽  
pp. 81-86
Author(s):  
A N Gorenchuk ◽  
P V Kulikov ◽  
S D Zhogolev ◽  
R M Aminev ◽  
A A Kuzin ◽  
...  
Keyword(s):  
Environmental Sustainability ◽  
Respiratory Diseases ◽  
Respiratory Infections ◽  
Genetic Material ◽  
Influenza Viruses ◽  
Respiratory Pathogens ◽  
Acute Respiratory Diseases ◽  
Socio Demographic Factors ◽  
Comparison Of The Results ◽  
Active Implementation

The species affiliation of respiratory pathogens isolated from patients and carriers in the military units of the Western Military District in 2014-2019 was studied. The analysis of long-term and seasonal dynamics of their circulation is carried out. It was found that S. pneumoniae and adenoviruses are more often detected in acute respiratory diseases in conscripts. The genetic material of adenoviruses was found in 31,9% of samples, influenza viruses in 13,3%, rhinoviruses in 11,2%, respiratory syncytial viruses in 1,7%, metapneumoviruses in 0,9%, parainfluenza viruses 0,7%, bocaviruses0,5%, coronaviruses 0,1%, S. pneumoniae 33,9%, H. influenzae 13%, M. pneumoniae 9%, C. pneumoniae - in 3,3%, N. meningitidis - in 16%. Comparison of the results of work with studies carried out by domestic research groups among the civilian population in the same period showed that the circulation of various respiratory viruses depends on the year, season, and is also influenced by socio-demographic factors. A direct high functional correlation was found between the dynamics of circulation of adenovirus and S. pneumoniae in different years and epidemic seasons. Evidence has been obtained of the active implementation of the process of self-maintenance of the reservoir of infections and the multifactorial nature of the overall environmental sustainability of the system in organized military teams. In the etiological structure of respiratory infections, the proportion of pathogens varies depending on the season in different years, the characteristics of the formation and composition of organized groups, as well as epidemic periods.

scholarly journals EFFECTIVENESS OF FIXED COMBINATION OF FORMULATIONS FOR COUGHING

2020 ◽  
Vol 20 (4) ◽  
pp. 45-48
Author(s):  
V. M. Zhdan ◽  
Н. S. Khaimenova ◽  
M. Yu. Babanina ◽  
O.A. Kyrian ◽  
I. V. Ivanitskiy
Keyword(s):  
Respiratory Disease ◽  
Respiratory Diseases ◽  
Comparison Group ◽  
Clinical Symptoms ◽  
Fixed Combination ◽  
Pathological Process ◽  
Efficacy And Safety ◽  
Bronchial Secretion ◽  
Acute Respiratory Diseases ◽  
The Difference

There are many respiratory diseases, which despite the difference in aetiology, pathogenesis, the peculiarities in progression may have some common features, resulting in the localization of the pathological process in the respiratory systems. These common signs include changes in bronchial secretion that ultimately leads to mucostasis and burdens the course of any respiratory disease. There are very few combined formulations capable of impacting several mechanisms of mucostasis at once. One of them is Ascoril possessing a double effect of bronchodilator and expectorant. The aim of this study was to evaluate the clinical efficacy and safety of Ascoril therapy for patients with acute respiratory diseases. The study included 105 patients aged 25 ± 0.5 to 55 ± 1.6 years with mild or moderate acute respiratory disease, who had acute respiratory diseases with cough due to laryngitis, pharyngitis, tracheitis, bronchitis. Patients of the 1st group (75 patients, the main group) received the treatment with Ascoril, the patients of the 2nd group (30 patients, the comparison group) received Bromhexine. The patients in both groups were comparable by age and sex. The patients treated with Ascoril showed the disappearance of cough symptoms 3 – 4 days earlier than the patients in the comparison group (p < 0.05). The total score assessment of clinical symptoms during the treatment demonstrated the administration of Ascoril promoted the effectiveness of therapy, which was found significantly higher than in the 2nd group (p < 0.05). We can conclude Ascoril reduces the duration of the disease, cut down the need in antibiotics, lowers the manifestations of bronchial hyper reactivity, and promotes faster clinical recovery, the last but not the least, it is safe.

scholarly journals Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis

2021 ◽  
Vol 5 (5) ◽  
pp. 335-347
Author(s):  
N.A. Geppe ◽  
◽  
A.L. Zaplatnikov ◽  
E.G. Kondyurina ◽  
O.I. Afanasieva ◽  
...  
Keyword(s):  
Systematic Review ◽  
Therapeutic Efficacy ◽  
Disease Duration ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Meta Analysis ◽  
Acute Respiratory Infections ◽  
Efficacy And Safety ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections

Aim: to evaluate the efficacy and safety of Anaferon and Anaferon for children for the prevention and treatment of of acute respiratory viral infections (ARVI)/influenza using meta-analysis. Patients and Methods: the meta-analysis included data from 11 randomized clinical trials (RCTs) involving 3079 patients aged 1 month to 69 years, of which: 1729 people were included in the meta-analysis of the preventive drugs efficacy, 1550 patients — in the meta-analysis of the therapeutic efficacy of Anaferon for children. The evaluation of the therapeutic efficacy was conducted according to the criteria "disease duration" and/or "fever duration", the evaluation of the preventive efficacy was conducted according to the criterion "the proportion of patients not falling ill with ARVI/influenza". The safety was evaluated taking into account the number of adverse events (AEs). Statistical methods included the exact Fisher criterion, the Student criterion, fixed and random effects models, the Z-test, the Cochrane-Mantel-Hensel criterion, Cochrane Q-statistics and the I2 coefficient, the Breslow-Day test, the calculation of relative risk (RR), odds ratios (OR) and their 95% confidence intervals (CI). Results: according to the criterion "the proportion of patients not falling ill with ARVI/influenza", the RR of Anaferon for children was 1.2 [95% CI 1.2; 1.3] with an OR of 2.2 [95% CI 1.7; 2.9], while for Anaferon, the RR was 6.7 [95% CI 3.8; 11.8] with an OR of 20.1 [95% CI 9.2; 44.0]. At the same time, the proportion of patients without ARVI/influenza during Anaferon intake exceeded that in the absence of preventive intervention by almost 8 times, and during Anaferon for children intake — 1.3 times vs. placebo. When evaluating the therapeutic effect of Anaferon for children, it was found that the average disease duration was 1.4 times shorter than during placebo intake, and was 4.71±2.53 days (p<0,001). The average fever duration was 2.19±1.21 days vs. 3.22±1.81 days during placebo intake (p<0,001). According to the criterion "disease duration", the weighted average effect value was 1.05 [95% CI 0.44; 1.67], according to the criterion "fever duration" — 0.97 [95% CI 0.61; 1.33] (p<0.001, p-value of the two-tailed Z-test; random effects model). The therapeutic efficacy of Anaferon for children did not depend on the etiology of ARVI, the symptoms, and the presence of comorbidity (asthma). The total number of AEs is similar to those in the comparison group. Conclusion: the conducted review and meta-analysis concerning the efficacy and safety of Anaferon and Anaferon for children for the treatment and prevention of ARVI/influenza allow us to conclude the following: 1) Anaferon for children is effective and safe for the treatment of influenza and other acute respiratory infections, regardless of the pathogen and the presence of comorbidity (asthma); 2) Anaferon and Anaferon for children are effective and safe for the prevention of acute respiratory infections/influenza, including patients with concomitant bronchopulmonary pathology and frequently ill children. KEYWORDS: ARVI, influenza, prevention, treatment, meta-analysis, Anaferon, Anaferon for children. FOR CITATION: Geppe N.A., Zaplatnikov A.L., Kondyurina E.G. et al. Efficacy and safety of Anaferon for children and Anaferon for the prevention and treatment of influenza and other acute respiratory viral infections: systematic review and meta-analysis. Russian Medical Inquiry. 2021;5(5):335–347 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-335-347.

Halotherapy in the rehabilitation of children in educational institutions

2020 ◽  
pp. 30-36
Author(s):  
Maya Khan ◽  
Irina Ivanova ◽  
Natalya Mikitchenko ◽  
Anna Dedurina ◽  
Natalya Lyan
Keyword(s):  
Respiratory Disease ◽  
Therapeutic Effect ◽  
Respiratory Diseases ◽  
Educational Institutions ◽  
Optimal Parameters ◽  
Acute Respiratory Disease ◽  
Acute Respiratory Diseases ◽  
Anti Inflammatory ◽  
The Impact

The aim of the study was to assess the impact of halotherapy performed in halocabinets on the health of children who often suffer from acute respiratory diseases. Based on the data obtained, the pronounced anti-inflammatory and sanogenetic effect of the factor was established, and the optimal parameters and halotherapy regimens were determined depending on the presence of symptoms of acute respiratory disease. Follow-up observations have confirmed the durability of the therapeutic effect.

Sign in / Sign up

Export Citation Format

Share Document